BNET Industries

Intercell Ag

ICLL is in the Pharma Industry

Last Fiscal Year Sales:$77.8M
  • Public
  • AT
Dow Jones Description

Biotechnology Services

Number of Employees 250
Contact Information

Campus Vienna Biocenter 2

Vienna 1030

www.intercell.c...

(43) 20620 0

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development...

    5/30/09 - Joint Venture / Alliance - View Story

News & Analysis

intercell ag - All News and Analysis

  • Intercell AG Joins OTCQX

    - 2009-08-10

    NEW YORK, Aug. 10 /PRNewswire/ -- Pink OTC Markets Inc., the leading electronic inter-dealer quotation system, trading technology and financial information provider for over-the-counter OTC securities, today announced that Intercell AG (VSE: ICLL, OTCQX: INRLY), a leading Austrian biotechnology company, has chosen to list its American Depositary...

    Tags: Intercell Ag

  • Cdc Recommendation Includes Intercell's Ixiaro Vaccination

    - 2009-08-01

    Intercell AG (VSE: ICLL) has announced that the U.S. Centers for Disease Control and Prevention CDC Advisory Committee on Immunization Practices ACIP voted to update its previous recommendations and include IXIARO, a new Japanese Encephalitis JE vaccine for travelers to countries in Asia where the disease is endemic,...

    Tags: Intercell Ag

  • Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC's Advisory Committee on Immunization Practices

    - 2009-06-24

    - Expanded Guidelines to include availability of IXIAROR vaccine for Japanese Encephalitis - IXIARO now available in the U.S. for travelers to Asia, military personnel, others at high risk regardless of the length of visit ATLANTA, June 24 /PRNewswire/ -- Intercell AG (VSE: ICLL) today...

    Tags: Intercell Ag

  • Intercell AG

    - 2009-04-06

    Intercell AG. (Vienna, Austria) won approval for a vaccine against Japanese encephalitis. The vaccine, called Ixiaro, would be the only vaccine for the mosquito-transmitted disease available in the United States.

    Tags: Intercell Ag

  • QUMAS and EXTEDO/IABG-LSS Deliver Integrated Document and Submission Management Solution to Intercell

    - 2007-01-22

    QUMAS, a leading provider of quality management and regulatory affairs solutions, today announced that biotechnology company Intercell AG has implemented the QUMAS Compliance SuiteTM and the eCTDmanager SuiteTM from EXTEDO/IABG Life Sciences Solutions (IABG-LSS). The combined solution provides Intercell with an integrated electronic document and submission management system to support...

    Tags: Intercell Ag

Decision Makers

Name (plus bio) Position
Alexander Von Gabain CEO
Reinhard Kandera CFO
James R. Sulat Developer
David R. Ebsworth Director

Board of Directors

Name (plus bio) Position
Ernst-Gunter Afting Board of Directors
Michael Greco Board of Directors
Michel Greco Board of Directors

Organization Position Status
Intercell Ag CEO Current
Pelias AG Board of Directors Current
Biovertis AG Board of Directors Current
Intercell Ag Board of Directors Current
University of Vienna Chairman of the Department of Microbiology and Genetics Former

Organization Position Status
Emcools - Emergency Medical Cooling Systems AG President of the Supervisory Board Current
Intercell Ag CFO Current
Intercell Ag Head of Finance Former

Organization Position Status
Alta Partners President, Chief Executive Officer and Director Current
Memory Pharmaceuticals Corp. Chief Financial Officer Current
Intercell Ag Developer Current
Maxygen, Inc. Chairman Current
Maxygen, Inc. Director Current
Momenta Pharmaceuticals, Inc. Board of Directors Current
Intercell Ag Director Current
Memory Pharmaceuticals Corp. Board of Directors Current
Memory Pharmaceuticals Corp. Chief Executive Officer Former
R.R. Donnelley & Sons Co. Chief Financial Officer Former
Chiron Chief Financial Officer Former
R.R. Donnelley & Sons Co. Senior Executive Vice President Former
Moore Wallace Senior Executive Vice President Former
Chiron Vice President Former
Stanford University M.B.A. Former
Yale University B.S. Former

Appointed 2002. Formerly worldwide head of the pharmaceutical division of Bayer AG. Dr Ebsworth has over 20 years of pharmaceutical industry experience. Prior to his last position as President and General Manager of the Pharmaceutical Business Group for Bayer AG in Leverkusen, Germany, Dr Ebsworth held a series of global positions within the same group in Canada, Europe and the United States. Dr Ebsworth is a non-executive director of CuraGen Corporation.

Organization Position Status
CuraGen Corporation Non-Executive Director Current
SkyePharma PLC Non-Executive Director Current
Xention Limited Chairman of Xention's Board of Directors Current
Wilex AG Chairman Current
Intercell Ag Director Current
Renovo Plc Board of Directors Current
Pir Interims Board of Directors Current
CuraGen Corporation Committee Chair for Compensation Committee Former
Curacyte AG Chairman Former
SkyePharma PLC Board of Directors Former
University of Surrey Ph.D. Former
Surrey University PhD Former
University of New Haven Doctorate In Humane Letters Former
University of Surrey Bsc In Chemistry Former

Organization Position Status
Intercell Ag Board of Directors Current
Sequenom, Inc. Board of Directors Current
University of Freiburg M.D. Former

Organization Position Status
Intercell Ag Board of Directors Current

Organization Position Status
Glycovaxyn AG Chairman of the Board Current
VaxGen, Inc. Director Current
Intercell Ag Board of Directors Current
Aventis Pasteur Deputy CEO Former
Aventis Pasteur President Former
Aventis Pasteur Chief Operating Officer Former
advertisement
IndustryTop Rated
advertisement